A biomimetic tissue scaffold for repairing an elongated tissue in need of repair can comprise a plurality of coiled flexible polymeric ribbons having a surface on which is formed an array of nanofibers, the ribbons forming a tubular body defining a first open end in which a first end of the elongated tissue is receivable, a second open end in which a second end of the elongated tissue is receivable, and a lumen extending between the first and second open ends.

The present application provides biodegradable composite material comprising bioresorbable magnesium or magnesium alloy embedded in bioresorbable glass fiber reinforced polymer matrix, and a bioresorbable implant comprising the composite material. The present application also provides use of the composite material, and methods for preparing the composite material and a medical device of a part thereof.

A polymer composition contains polylactic acid and a dilactide/ε-caprolactone copolymer, in which a content of the polylactic acid relative to a total of 100 mass % of the polylactic acid and the dilactide/ε-caprolactone copolymer is 20 to 40 mass %, and in which the dilactide/ε-caprolactone copolymer satisfies (1) an R value represented by a following formula is 0.45 or more and 0.99 or less:

[00001]$R=\left[\mathrm{AB}\right]\text{/}\left(2\left[A\right]\left[B\right]\right)\times 100$

where [A] is a molar fraction (%) of a dilactide residue in the dilactide/ε-caprolactone copolymer, [B] is a molar fraction (%) of an ε-caprolactone residue in the dilactide/ε-caprolactone copolymer, and [AB] is a molar fraction (%) of a structure in which a dilactide residue and an ε-caprolactone residue are adjacent to each other (A-B and B-A) in the dilactide/ε-caprolactone copolymer, and (2) at least one of the dilactide residue and the ε-caprolactone residue has a degree of crystallization of less than 14%.

A magnesium alloy contains a small amount of lithium, zinc, calcium, and manganese. For example, the magnesium alloy may include between 1-5 wt. % lithium, between 0.2-2.0 wt. % zinc, between 0.1-0.5 wt. % calcium, and between 0.1-0.8 wt. % manganese. These alloying elements are all nutrient elements, such that the present alloy can be safely broken down in vivo, then absorbed and/or expelled from the body. Li, Zn, Ca and Mn each contribute to solid-solution strengthening of the alloy. Ca also acts as a grain refiner, while Zn and Ca both form strengthening and corrosion-controlling intermetallic compounds. Optionally, the alloy may also include a small amount of yttrium for added strength and corrosion resistance.

A coating for an expandable portion of a catheter comprising a lipophilic matrix and a plurality of micro-reservoirs dispersed in the lipophilic matrix is disclosed. The plurality of micro-reservoirs comprises an active agent. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.

The disclosure describes new devices and methods for vascularizing devices and methods for implanted diagnostics and therapeutics. The present disclosure provides, in certain embodiments, a device containing a degradable shell and a non-degradable core. In certain embodiments, the non-degradable core can include encapsulated therapeutic cells and/or biosensors, wherein the degradable shell serves as a scaffold for blood vessel growth, resulting in enhanced blood flow to the cells and/or biosensors.

Materials and methods are provided to direct the formation of new lymphatics and to reconnect the disrupted lymphatic network. These materials and methods enable to improve survival of lymph nodes and lymph node fragments and their integration into a lymphatic network, following lymph node and lymph node fragments transplantation. The treatment or prevention of lymphedema is also addressed. In certain embodiments, a bundle of fibers or fibrils presented in the composition is effective to stimulate and direct the formation of new lymphatic and blood vessels. The bundle of fibers or fibrils presented in the composition is effective to promote survival of the lymph node or lymph node fragments and integration of the lymph node or lymph node fragments into a lymphatic network in the mammalian subject, at the site of transfer or transplantation.

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles.

A composite comprising: a barrier, said barrier being configured to selectively pass water, and said barrier being degradable in the presence of water; a matrix material for disposition within said barrier, wherein said matrix material has a flowable state and a set state, and wherein said matrix material is degradable in the presence of water; and at least one reinforcing element for disposition within said barrier and integration with said matrix material, wherein said at least one reinforcing element is degradable in the presence of water, and further wherein, upon the degradation of said at least one reinforcing element in the presence of water, provides an agent for modulating the degradation rate of said matrix material in the presence of water.

The present invention relates to biocompatible compositions comprising one or more crystallin proteins, and the use of such compositions in therapeutic and research methods, for example in surgical methods, in sustained release drug delivery, and in cell-based methods.